Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aduro Biotech (ADRO)

Aduro Biotech (ADRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 236,614
  • Shares Outstanding, K 16,212
  • Annual Sales, $ 17,260 K
  • Annual Income, $ -82,370 K
  • 60-Month Beta 0.40
  • Price/Sales 13.16
  • Price/Cash Flow N/A
  • Price/Book 5.08
Trade ADRO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.90
  • Number of Estimates 3
  • High Estimate -0.80
  • Low Estimate -0.95
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +32.68%
on 09/24/20
15.73 -7.21%
on 10/02/20
+1.30 (+9.74%)
since 09/04/20
3-Month
11.00 +32.68%
on 09/24/20
17.20 -15.15%
on 08/18/20
+2.10 (+16.76%)
since 07/02/20
52-Week
4.51 +223.94%
on 10/25/19
20.20 -27.75%
on 02/20/20
+9.55 (+189.01%)
since 10/04/19

Most Recent Stories

More News
Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?

Smart Beta ETF report for DVYE

DVYE : 26.22 (-1.44%)
ADRO : 14.60 (+4.18%)
IEMG : 48.70 (-0.73%)
VWO : 41.40 (-0.60%)
Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?

Smart Beta ETF report for DVYE

DVYE : 26.22 (-1.44%)
ADRO : 14.60 (+4.18%)
IEMG : 48.70 (-0.73%)
VWO : 41.40 (-0.60%)
GLTR : 85.06 (-0.32%)
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”

ADRO : 14.60 (+4.18%)
KDNY : 17.51 (+0.11%)
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

One-for-Five Reverse Stock Split to be Effective October 2, 2020

ADRO : 14.60 (+4.18%)
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing...

ADRO : 14.60 (+4.18%)
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon...

ADRO : 14.60 (+4.18%)
Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

BERKELEY, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon...

ADRO : 14.60 (+4.18%)
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

ADRO : 14.60 (+4.18%)
Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

BERKELEY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon...

ADRO : 14.60 (+4.18%)
Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results

BERKELEY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon...

ADRO : 14.60 (+4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 15.40
1st Resistance Point 15.00
Last Price 14.60
1st Support Level 14.06
2nd Support Level 13.52
3rd Support Level N/A

See More

52-Week High 20.20
Last Price 14.60
Fibonacci 61.8% 14.20
Fibonacci 50% 12.35
Fibonacci 38.2% 10.50
52-Week Low 4.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar